^
Association details:
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

Mismatch repair deficient rectal cancer is resistant to induction combination chemotherapy

Published date:
10/01/2018
Excerpt:
Twenty of the 49 patients received induction chemotherapy with 5FU and oxaliplatin...28% (n = 5) of patients demonstrated progressive disease while on therapy. The majority of these cases, 82% (41/50) harbored germline mutations in the MMR genes and the observed prevalence of germline MSH2 and MSH6 mutations was significantly higher in the rectal (n = 41)...Patients with MMR-D rectal tumors appear to have a high chance of disease progression on induction chemotherapy.
DOI:
10.1093/annonc/mdy281.047